Efficacy and Safety of RBX2660 in PUNCH CD3, a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial with a Bayesian Primary Analysis for the Prevention of Recurrent Clostridioides difficile Infection

BACKGROUND: Recurrent Clostridioides difficile infection, associated with dysbiosis of gut microbiota, has substantial disease burden in the USA. RBX2660 is a live biotherapeutic product consisting of a broad consortium of microbes prepared from human stool that is under investigation for the reduct...

Descripción completa

Detalles Bibliográficos
Autores principales: Khanna, Sahil, Assi, Maha, Lee, Christine, Yoho, David, Louie, Thomas, Knapple, Whitfield, Aguilar, Humberto, Garcia-Diaz, Julia, Wang, Gary P., Berry, Scott M., Marion, Joe, Su, Xin, Braun, Tricia, Bancke, Lindy, Feuerstadt, Paul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9607700/
https://www.ncbi.nlm.nih.gov/pubmed/36287379
http://dx.doi.org/10.1007/s40265-022-01797-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9607700/
https://www.ncbi.nlm.nih.gov/pubmed/36287379
http://dx.doi.org/10.1007/s40265-022-01797-x

Ejemplares similares